Rimtoregtide

N/A

Report date: 2023/03/30 13:57:58
NME

Base Information

Drug NameRimtoregtide
Drug Alias NameRegIII/PAP蛋白活性片段的多肽类似物HTD-4010
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionRegenerating islet-derived protein 3-alpha agonists
TargetsRegenerating islet-derived protein 3-alpha
Therapy Area/IndicationsDiabetes Mellitus, Type 2PancreatitisFatty Liver, Alcoholic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShenzhen Hepalink Pharmaceutical Group Co LtdShenzhen Hightide Biopharmaceutical Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Hightide Biopharmaceutical Ltd
Inactive CompaniesHightide Biopharma Pty Ltd
Active IndicationsPancreatitisFatty Liver, Alcoholic
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A